MedTrace Logo

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

NCT06400472 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 495

Last updated 2026-01-14

No results posted yet for this study

Summary

The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

Conditions

  • Ovarian Neoplasms
  • Endometrial Neoplasms
  • Uterine Cervical Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Triple Negative Breast Neoplasms
  • Pancreatic Neoplasm
  • Colorectal Neoplasms

Interventions

DRUG

LY4170156

Intravenous

DRUG

bevacizumab

IV

DRUG

carboplatin

IV

DRUG

Itraconazole

oral

DRUG

pembrolizumab

IV

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-20
Primary Completion
2027-02-28
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Italy
  • Japan
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06400472 on ClinicalTrials.gov